348 related articles for article (PubMed ID: 35993192)
1. Insights into mechanisms of graft-versus-host disease through humanised mouse models.
Elhage A; Sligar C; Cuthbertson P; Watson D; Sluyter R
Biosci Rep; 2022 Sep; 42(9):. PubMed ID: 35993192
[TBL] [Abstract][Full Text] [Related]
2. Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice.
Cuthbertson P; Button A; Sligar C; Elhage A; Vine KL; Watson D; Sluyter R
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339054
[TBL] [Abstract][Full Text] [Related]
3. P2X7 receptor antagonism increases regulatory T cells and reduces clinical and histological graft-versus-host disease in a humanised mouse model.
Cuthbertson P; Geraghty NJ; Adhikary SR; Casolin S; Watson D; Sluyter R
Clin Sci (Lond); 2021 Feb; 135(3):495-513. PubMed ID: 33463682
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Co-activation of macrophages and T cells contribute to chronic GVHD in human IL-6 transgenic humanised mouse model.
Ono R; Watanabe T; Kawakami E; Iwasaki M; Tomizawa-Murasawa M; Matsuda M; Najima Y; Takagi S; Fujiki S; Sato R; Mochizuki Y; Yoshida H; Sato K; Yabe H; Kato S; Saito Y; Taniguchi S; Shultz LD; Ohara O; Amagai M; Koseki H; Ishikawa F
EBioMedicine; 2019 Mar; 41():584-596. PubMed ID: 30772305
[TBL] [Abstract][Full Text] [Related]
6. Increased P2X7 expression in the gastrointestinal tract and skin in a humanised mouse model of graft-versus-host disease.
Cuthbertson P; Adhikary SR; Geraghty NJ; Guy TV; Hadjiashrafi A; Fuller SJ; Ly D; Watson D; Sluyter R
Clin Sci (Lond); 2020 Jan; 134(2):207-223. PubMed ID: 31934722
[TBL] [Abstract][Full Text] [Related]
7. Increased splenic human CD4
Geraghty NJ; Belfiore L; Adhikary SR; Alexander SI; Sluyter R; Watson D
Transpl Immunol; 2019 Jun; 54():38-46. PubMed ID: 30743002
[TBL] [Abstract][Full Text] [Related]
8. Altered donor P2X7 activity in human leukocytes correlates with P2RX7 genotype but does not affect the development of graft-versus-host disease in humanised mice.
Adhikary SR; Geraghty NJ; Cuthbertson P; Sluyter R; Watson D
Purinergic Signal; 2019 Jun; 15(2):177-192. PubMed ID: 31001750
[TBL] [Abstract][Full Text] [Related]
9. Post-transplant cyclophosphamide limits reactive donor T cells and delays the development of graft-versus-host disease in a humanized mouse model.
Adhikary SR; Cuthbertson P; Nicholson L; Bird KM; Sligar C; Hu M; O'Connell PJ; Sluyter R; Alexander SI; Watson D
Immunology; 2021 Oct; 164(2):332-347. PubMed ID: 34021907
[TBL] [Abstract][Full Text] [Related]
10. Increased risk of lethal graft-versus-host disease-like syndrome after transplantation into NOD/SCID mice of human mobilized peripheral blood stem cells, as compared to bone marrow or cord blood.
Gorin NC; Piantadosi S; Stull M; Bonte H; Wingard JR; Civin C
J Hematother Stem Cell Res; 2002 Apr; 11(2):277-92. PubMed ID: 11983099
[TBL] [Abstract][Full Text] [Related]
11. The A
Geraghty NJ; Adhikary SR; Watson D; Sluyter R
Int Immunopharmacol; 2019 Jul; 72():479-486. PubMed ID: 31051404
[TBL] [Abstract][Full Text] [Related]
12. Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2rγ(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease.
Covassin L; Laning J; Abdi R; Langevin DL; Phillips NE; Shultz LD; Brehm MA
Clin Exp Immunol; 2011 Nov; 166(2):269-80. PubMed ID: 21985373
[TBL] [Abstract][Full Text] [Related]
13. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
Front Immunol; 2021; 12():785774. PubMed ID: 34987512
[TBL] [Abstract][Full Text] [Related]
14. Early myeloid-derived suppressor cells (HLA-DR
Wang K; Lv M; Chang YJ; Zhao XY; Zhao XS; Zhang YY; Sun YQ; Wang ZD; Suo P; Zhou Y; Liu D; Zhai SZ; Hong Y; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
J Hematol Oncol; 2019 Mar; 12(1):31. PubMed ID: 30885244
[TBL] [Abstract][Full Text] [Related]
15. Effective treatment against severe graft-versus-host disease with allele-specific anti-HLA monoclonal antibody in a humanized mouse model.
Nakauchi Y; Yamazaki S; Napier SC; Usui J; Ota Y; Takahashi S; Watanabe N; Nakauchi H
Exp Hematol; 2015 Feb; 43(2):79-88.e1-4. PubMed ID: 25448490
[TBL] [Abstract][Full Text] [Related]
16. Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia.
Pang Y; Holtzman NG
Best Pract Res Clin Haematol; 2023 Jun; 36(2):101475. PubMed ID: 37353287
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of graft-versus-host-disease in NOD scid IL-2Rγ(-/-) (NSG) mice by ex vivo modulation of human CD4(+) T cells.
Hilger N; Glaser J; Müller C; Halbich C; Müller A; Schwertassek U; Lehmann J; Ruschpler P; Lange F; Boldt A; Stahl L; Sack U; Oelkrug C; Emmrich F; Fricke S
Cytometry A; 2016 Sep; 89(9):803-15. PubMed ID: 27560708
[TBL] [Abstract][Full Text] [Related]
18. Modeling Human Graft-Versus-Host Disease in Immunocompromised Mice.
Norelli M; Camisa B; Bondanza A
Methods Mol Biol; 2016; 1393():127-32. PubMed ID: 27033222
[TBL] [Abstract][Full Text] [Related]
19. Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex.
King MA; Covassin L; Brehm MA; Racki W; Pearson T; Leif J; Laning J; Fodor W; Foreman O; Burzenski L; Chase TH; Gott B; Rossini AA; Bortell R; Shultz LD; Greiner DL
Clin Exp Immunol; 2009 Jul; 157(1):104-18. PubMed ID: 19659776
[TBL] [Abstract][Full Text] [Related]
20. PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Ry
Burger DR; Parker Y; Guinta K; Lindner D
Biol Blood Marrow Transplant; 2018 Feb; 24(2):260-266. PubMed ID: 29128556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
